Cresco Labs (CRLBF) Equity Income (2020)

Cresco Labs (CRLBF) posted Equity Income of -$927000.0 for Q4 2020, down 591.79% on a QoQ basis from -$134000.0 in Q3 2020.

Cresco Labs (CRLBF) Equity Income (2020) Analysis & Trends

Cresco Labs' Equity Income history runs 1 years deep, the most recent figure standing at -$927000.0 for Q4 2020.

Quarterly Equity Income changed N/A year-over-year to -$927000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was -$1.2 million (changed N/A YoY) and the FY2020 annual result came in at -$927000.0, changed N/A from the prior year.
Equity Income was -$927000.0 for Q4 2020 at Cresco Labs, down from -$134000.0 in the prior quarter.
Across five years, Equity Income topped out at $24000.0 in Q2 2020 and bottomed at -$927000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Cresco Labs	254.96 Mn	99.57 Mn	75.45 Mn	-

Download Data